secwatch.observer — SEC 8-K summary
======================================

Issuer:     Larimar Therapeutics, Inc. (LRMR)
CIK:        0001374690
Form:       8-K
Filed at:   2024-03-14T23:59:59+00:00
Accession:  0000950170-24-031467
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Larimar reports positive Phase 2 data for nomlabofusp; $161.6M financing extends runway into 2026
--------------------------------------------------------------------------------

- Phase 2 dose exploration study met endpoints: dose-dependent frataxin increases in skin and buccal cells; 50 mg cohort saw levels >33% of healthy volunteers in all patients at Day 14.
- FDA discussions initiated for using tissue frataxin as surrogate endpoint for accelerated approval; BLA submission targeted for 2H 2025.
- Open-label extension (OLE) study of 25 mg daily nomlabofusp dosed first patient in March 2024; interim data expected Q4 2024.
- Raised $161.6M net proceeds from public offering in Feb 2024; cash position $86.8M at Dec 31, 2023 before offering.
- Q4 2023 net loss $13.0M ($0.30/share) vs $9.4M ($0.21/share) in Q4 2022; R&D expenses $10.6M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374690/000095017024031467/0000950170-24-031467-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374690/000095017024031467/lrmr-20240314.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-031467

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer